8-K ·Filed Apr 21, 2026

PULM

Pulmatrix, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001493152-26-018202
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

Monitor upcoming filings for further details on the merger with Eos SENOLYTIX and any additional capital raises, as the $1 million raise is modest for a biotech company and may indicate ongoing funding challenges.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PULM ▲ +16.67% at T+60d
NEUTRAL call ✓ call won +16.67% · α vs SPY +9.77% · entry $1.38 → $1.61
Entry anchored
Apr 20, 02:24 PM ET
via exchange tick
T+1d
+1.45%
call +1.45% · α +0.43%
$1.40
settled 5mo ago
T+5d
-7.25%
call -7.25% · α -8.33%
$1.28
settled 5mo ago
T+20d
-8.70%
call -8.70% · α -13.61%
$1.26
settled 5mo ago
T+60d
+16.67%
call +16.67% · α +9.77%
$1.61
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Pulmatrix, Inc. closed a $1 million private placement of Series B Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. as part of its planned merger. The preferred shares are convertible into common stock at $2.20 per share and carry voting rights.

Key Facts

  • Pulmatrix closed a private placement of Series B Preferred Stock on April 16, 2026
  • The offering raised approximately $1 million in gross proceeds
  • The investment was made by an affiliate of Eos SENOLYTIX, Inc.
  • The Series B Preferred Stock is convertible into common stock at $2.20 per share
  • The transaction is part of a planned merger between Pulmatrix and Eos
  • Proceeds will be used for working capital and general corporate purposes

Financial Impact

Approximately $1 million in gross proceeds from the private placement

cashdilutionequity

Risk Factors

  • The small size of the financing ($1 million) may not be sufficient to sustain operations long-term
  • Potential dilution to existing shareholders upon conversion of preferred shares
  • Uncertainty around the completion of the planned merger with Eos SENOLYTIX

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-018202
Exhibit: ex99-1.htm0001493152-26-018202
Document: 0001493152-26-018202-index-headers.html0001493152-26-018202
Document: 0001493152-26-018202-index.html0001493152-26-018202
Document: 0001493152-26-018202.txt0001493152-26-018202
9 reports for PULM
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+20▲ +11.15%Aug 7, 2026
Filters
Rows
Reports for PULM — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
S-4/A
BEARISH ★ 7/10
$1.40 $1.45▼ −3.58%▼ −4.70%$1.57 (−12.54%)
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$1.51 $1.50▼ −0.66%▲ +1.30%$1.57 (+3.97%)
Aug 13, 2026
7w ago
Press Release
BEARISH ★ 6/10
$1.51 $1.50▲ +0.66%▼ −1.30%$1.57 (−3.97%)
Aug 7, 2026
8w ago
S-3/A
BEARISH ★ 5/10
$1.57 $1.56▲ +0.64%▲ +0.59%$1.57 (−0.00%)
Jun 16, 2026
15w ago
10-K/A
NEUTRAL ★ 2/10
$1.50 $1.53▲ +2.00%▲ +3.04%$1.57 (+4.67%)
Jun 5, 2026
17w ago
425
NEUTRAL ★ 4/10
$1.33 $1.40▲ +5.26%▲ +4.69%$1.57 (+18.05%)
Jun 4, 2026
17w ago
S-3
BEARISH ★ 5/10
$1.32 $1.38▼ −4.55%▼ −7.10%$1.57 (−18.94%)
May 15, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$1.25 $1.34▲ +7.20%▲ +6.24%$1.57 (+25.60%)
Apr 21, 2026
23w ago
8-K
NEUTRAL ★ 5/10
$1.38 $1.28▼ −7.25%▼ −8.33%$1.57 (+13.77%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (64h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access